DIRS.INFO The most relevant business & tech news

☆ Broke Gen Zers are skipping first dates and meeting each other virtually instead
▼ + stars: | 2024-04-01 | by ( Lindsay Dodgson | ) www.businessinsider.com time to read: +7 min

However, virtual dating can't replace the chemistry and spark of an in-person meeting. Carlotta Cattelani, the UK country manager at the dating app Fruitz, told BI that meeting virtually makes dates more accessible. AdvertisementA virtual date is a less formal chance to see if your match is searching for the same things you are, Cattelani said. She warns that speaking virtually cannot entirely replace meeting someone in person, so FaceTime dates should be used sparingly. It's easier to be "catfished" on social media, she said, because virtual dates cannot replace the chemistry, body language, and eye contact you might experience in real life.

Persons: Gen Zers, —, Z, Tina Wilson, Zers, Wilson, takeout, they're, Eunice, They're, you've, I've, Baker, I'm, Carlotta Cattelani, Cattelani, it's, Sebastian Garrido, Carrie Berk, Berk Organizations: Service, Business, BI Locations: Toronto

• But after the interview, Ohtani’s spokesperson “disavowed” Mizuhara’s account, then released a statement saying Ohtani had been the victim of theft. • Later on Wednesday, Mizuhara was fired as Ohtani’s interpreter. ESPN’s Thompson said the interpreter and Ohtani’s representatives did “a big 180” in what they were telling her. At first, Ohtani’s spokesperson told ESPN the player had transferred money to help pay off Mizuhara’s gambling debts, the outlet reported. “I’ve been told (Mizuhara) says something to the effect of ‘I’m sorry.

Persons: Shohei Ohtani, Ippei, “, Mathew Bowyer, Scott Villiard, Bowyer, Diane Bass, Ohtani, ”, Dave Roberts, • Mizuhara, Mizuhara, Ohtani’s, Bowyer “, ‘, Bass, “ Mathew Bowyer, ” Bass, ” Mizuhara, Tisha Thompson, Thompson, –, ESPN’s Thompson, Berk Brettler, Shohei, “ I’ve, ’ ” Thompson Organizations: CNN — Major League Baseball, Internal Revenue Service, Angeles Dodgers, ESPN, Los Angeles Times, “ Major League Baseball, Department of Investigations, IRS, Angeles Field Office, CNN, Los Angeles Dodgers, Dodgers, Ohtani’s, San Diego Padres, MLB, Ohtani, Padres, ” CNN, “ feds, Los Angeles Angels, Shohei’s, Angels, The Dodgers, Nippon, Ham Fighters, Japan’s Nippon Professional Baseball League Locations: California, Seoul, South Korea, San Diego, Mizuhara’s, Ippei

☆ General Electric's final spinoff is days away. It's not too late to profit from the move
▼ + stars: | 2024-03-19 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

GE stock has been on a tear, outperforming the market over the past year, as investors bet that the company's break-up will unlock still more value. Since the health-care spinoff, GE shares have risen above $170 from the $60s. He expects anyone buying GE Vernova shares in April will get "a 50% move over the next fourteen months." GE's aerospace business benefits from a dominant market position where it leads in both widebody and narrowbody jet engines. Still, GE Vernova was a weak spot for the company since 2015, according to analysts.

Persons: haven't, FactSet, Gordon Haskett, Don Bilson, GE's, Andrew Obin, Obin, I've, Tony Bancroft, Scott Deuschle, Deuschle, Bancroft, Larry Culp, Culp, GE Vernova, Michael Bloom Organizations: GE Vernova, New York Stock Exchange, GE, GE Healthcare Technologies, General Electric, GE Healthcare, Bank of America, GE Aerospace, Gabelli, Aerospace & Defense ETF, Deutsche Bank, Bank, America's

☆ Stocks making the biggest moves after hours: Robinhood, SentinelOne, Under Armour and more
▼ + stars: | 2024-03-13 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

UiPath — Shares popped 8% after the software company reported fourth-quarter results that beat analysts' expectations. UiPath posted adjusted earnings of 22 cents per share on $405 million in revenue, higher than the 16 cents per share on $384 million in revenue analysts polled by LSEG, formerly Refinitiv, had anticipated. SentinelOne — The cybersecurity name slipped 10% after posting guidance for the first quarter and full year that came in line with analysts' estimates, per LSEG. Robinhood — The trading platform's stock added about 8% after the company reported its selected monthly operating data for February 2024. The company posted a wider-than-expected loss in 2023 and missed its production targets by a considerable margin.

Persons: UiPath, SentinelOne, Armour, Stephanie Linnartz, Kevin Plank, Mohamed El, Robinhood, Fisker, Lennar, LSEG, —, Christina Cheddar, Berk, Darla Mercado Organizations: LSEG, Street

☆ Dollar General's brand is showing some cracks and may be a warning sign ahead of earnings
▼ + stars: | 2024-03-12 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +7 min

In collecting this data, the firm saw a deterioration in the Dollar General brand last year. As of Monday's close, Dollar General's stock is up more than 57% from a 52-week low of $101.09 reached in mid-October. Their research found that consumers felt the cleanliness of Dollar General's stores, a top five driver of satisfaction, lagged key peers Dollar Tree and Family Dollar, and fell 2% further in February. Until November, shoppers rated Family Dollar and Dollar General's product offerings more or less on a par with each other. In addition to Dollar General's own challenges, all dollar stores are likely being hurt by weaker spending among low income consumers.

Persons: Vasos, what's, Todd Vasos, Jeff Owen, Gordon Haskett, Chuck Grom, Grom, bode, Piper Sandler, Peter Keith, Keith, Morgan Stanley, Simeon Gutman, Gutman, Michael Lasser, Lasser, Matthew Boss, — CNBC's Michael Bloom Organizations: Dollar, DG, Occupational Safety, Health Administration, SNAP, UBS, JPMorgan

☆ A complete timeline of Bobby Berk's exit from 'Queer Eye' and the drama that's ensued
▼ + stars: | 2024-03-08 | by ( Olivia Singh | ) www.businessinsider.com time to read: +9 min

Read previewNetflix's "Queer Eye" reboot built a reputation as a feel-good show about a team of professionals, known as the Fab Five, giving people life makeovers. AdvertisementHis full statement read:"To the Queer Eye Community who have become family to me. It's with a heavy heart that I announce that season 8 will be my final season on Queer Eye. The day after Berk's exit was announced, a source told People magazine that "the parting was amicable." According to one source, Van Ness' temper would hit a boiling point at least once a week.

Persons: —, Bobby Berk, Karamo Brown, Tan, Jonathan Van Ness, Antoni Porowski, he's, Gilbert Flore, Getty Images Berk, I've, It's, Berk, Bobby, Jeremiah Brent, Eric Charbonneau, Paramount Pictures Brent, Rachel Zoe's, Rachel Zoe, He's, Nate Berkus, Ilana Panich, costars, Kevin Winter, Van Ness, Berk didn't, Van, Brent, what's, didn't, that's, Michelle Obama Organizations: Service, Business, Harmony Gold, Variety, Getty Images, Queer Eye, Netflix, Getty, Paramount Pictures, France Tan Locations: Tan France, Los Angeles, Las Vegas, France, France Tan France, Instagram, Tan, Van Ness, Berk

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom
▼ + stars: | 2024-02-16 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +3 min

On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity

☆ Stocks making the biggest moves midday: Cisco Systems, Twilio, Super Micro Computer and more
▼ + stars: | 2024-02-15 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Super Micro Computer — The technology name added 8.5% after Bank of America said shares could rise to $1,040, a Wall Street high. For the recent quarter, Applovin reported earnings of 49 cents per share and $953 million in revenue. However, the company beat first-quarter earnings and revenue estimates. JFrog — The software development stock skyrocketed 25% after topping Wall Street's fourth-quarter estimates. That topped FactSet estimates 12 cents per share in earnings on $93 million in revenue.

Persons: Twilio, Applovin, Deere, Tripadvisor, Albemarle —, — Coinbase, —, JFrog, Penn, Jesse Pound, Hakyung Kim, Alex Harring, Michelle Fox, Brian Evans, Christina Cheddar Berk Organizations: Cisco Systems, Cisco, LSEG, Bank of America, Wells, Currency, Deere, Albemarle, JPMorgan, Chrysler, Fiat, Penn Entertainment, ESPN Bet Locations: North Carolina

☆ Elanco's $1.3 billion deal may give the animal health company more flexibility as product launches ramp up
▼ + stars: | 2024-02-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Elanco Animal Health's decision to sell its aqua division will narrow its focus on pet health and livestock sustainability, as management prepares to launch several new products this year. ELAN 1Y mountain Elanco stock over the past year. One area it identified is pet health, a $15 billion market that has benefited from increasing pet ownership, especially among people who see their pets as family and value their animals' health care. 'Flexibility' to invest behind launches The product launches will also give Elanco a chance to prove itself. The pet health business is very competitive and, once approved, Zenrelia will compete directly with rival Zoetis' Apoquel.

Persons: Elanco, Jeff Simmons, Simmons, Credelio, Cornell University's Richard P, FactSet, Chris Schott, ELAN, Schott, Jefferies, Glen Santangelo, Eli Lilly, Jasper Hellweg, Hellweg, Zenrelia, Zoetis, — CNBC's Michael Bloom Organizations: Merck, CNBC, ELAN, Riney Canine Health, JPMorgan, Argus Locations: U.S

☆ Bobby Berk explains why he left ‘Queer Eye’
▼ + stars: | 2024-01-26 | by ( Marianne Garvey | ) edition.cnn.com time to read: +1 min

CNN —Designer Bobby Berk is sharing more about his decision to step away from “Queer Eye” after eight seasons. “Queer Eye has been the most amazing gift that I couldn’t have ever imagined,” Berk told Vanity Fair. Berk explained that after a seven-cycle contract that lasted through September 2022 had concluded, he thought the show would be over. Karamo Brown, Tan France, Bobby Berk, Jonathan Van Ness, Antoni Porowski in "Queer Eye." “We had mentally just prepared ourselves to move on—that’s why I left,” he said.

Persons: Bobby Berk, ” Berk, “ It’s, . Berk, Tan France, “, Tan, Berk, Karamo Brown, Jonathan Van Ness, Antoni Porowski, Ilana Panich, ”, maven Jonathan Van Ness Organizations: CNN, Netflix Locations: Tan France, France

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Youth suicide rates rose 62% from 2007 to 2021: 'People feel hopeless,' one recent grad says
▼ + stars: | 2023-12-05 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +9 min

Last year, suicide rates in the U.S. were the highest they had been since 1941, according to data from the Centers for Disease Control and Prevention. From 2007 through 2021, suicide rates for Americans ages 10 to 24 rose 62%, according to the CDC. Young people don't think they can make 'a significant difference'Financial instability has proven to be a large contributing factor in youth suicide. In 2014 and 2015, suicide rates at the Massachusetts Institute of Technology surpassed the national average, which was about 13 deaths per year, according to CDC data. Easier access to guns is linked to increased suicide rates, as well, as gun suicides reached an all-time high in 2022, according to CDC data.

Persons: Young, Katie Meyer, Ian Alexander Jr, Regina King, Ellis Lariviere, Mariana Fabiana, —, Fabiana, Gen Z, ideation, Michele Berk, Berk, Bessel, Van der Kolk, Gen, Carl Fleischer, Fleischer, Nate Bronstein, it's, It's, Carl Fleisher, Jennifer Breheny Wallace, Wallace Organizations: Stanford University, Centers for Disease Control, North Carolina State University, Columbia University, Massachusetts Institute of Technology, MIT, CDC, Boston Child Study, Facebook, Harvard, Yale University, University of California Locations: Brooklyn , New York, U.S, Palo Alto , California, Los Angeles, Chicago

☆ The investing world reacts to death of Berkshire legend Charlie Munger
▼ + stars: | 2023-11-28 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Several investors mourned the passing of famed investor Charlie Munger, vice chairman of Warren Buffett's Berkshire Hathaway , on Tuesday. "So sad to hear the news of the passing of Charlie Munger," El-Erian wrote. Mario Gabelli, chairman and CEO of Connecticut-based GAMCO Investors, wrote on Twitter: "Charlie Munger ….a titan has passed …all will miss Charlie." "Charlie Munger helped build an American institution, and through his wisdom and insights, inspired a generation of leaders. "Charlie Munger was a brilliant attorney," Annandale Capital chairman George Seay said Tuesday evening on Yahoo Finance.

Persons: Charlie Munger, Warren Buffett's Berkshire Hathaway, Berkshire Hathaway, Buffett, Munger, Ariel Investments, Charles Bobrinskoy, Mohamed El, PIMCO, Erian, Mario Gabelli, Charlie Munger …, Charlie, Tim Cook, Cook, Stephanie Link, Hightower, Whitney Tilson, Tilson, George Seay, Wesley Chan, Chan, —, Christina Cheddar Berk, Brian Evans, Alex Harring Organizations: Warren, Allianz, Twitter, Apple, Berkshire, Hightower Advisors, Berkshire Hathaway, CNBC, Yahoo Finance, Daily, Costco Locations: Munger, Connecticut, Berkshire, American, California, Annandale, FPV

☆ Want to pick a winning retail stock this holiday season? Watch for discounts and deflation
▼ + stars: | 2023-11-22 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +9 min

However, he added, they remain more upbeat compared with last holiday season and should spend more on gifts this year. According to FactSet, analysts anticipate there could be upside of more than 20% ahead, based on average price targets. The e-commerce giant is JPMorgan analyst Doug Anmuth's top pick for the holiday season. "We project US e-comm penetration at 23.4% of adj retail sales this holiday season, +90bps above the 22.5% in 2022," he said. "We think beauty has the potential to be a relevant gifting solution for cash-strapped consumers during the upcoming Holiday season," he said.

Persons: Chad Lusk, Alvarez, Lusk, Martis, LSEG, Inna Kuznetsova, Doug Anmuth's, Doug McMillon, Krisztina Katai, Katai, Michael Lasser, Ulta, Lasser, ToolsGroup's Kuznetsova, Marsal's Lusk, Michael Bloom Organizations: Shoppers, CNBC, Walmart, Target, Retailers, Centric Market Intelligence, Amazon, LSEG, JPMorgan, Deutsche Bank, Costco, UBS, Fed, Black Locations: Lusk, Ulta, Wayfair, Williams, Sonoma

☆ Here's what Wall Street is saying about obesity drug Wegovy following Novo Nordisk's key study
▼ + stars: | 2023-11-13 | by ( Alex Harring | ) www.cnbc.com time to read: +6 min

Wegovy contains semaglutide, the same active ingredient in Novo's type 2 diabetes drug Ozempic. A rising tide for Eli Lilly? Though the study was specifically about Wegovy, Wall Street sees a positive readthrough for similar medications from other providers, particularly Eli Lilly 's Zepbound. Similarly, UBS analyst Trung Huynh called the weekend data a "best-case" scenario for Eli Lilly. And the positive outcomes for both in the Wegovy study can be viewed as encouraging for how Zepbound should perform, the analyst added.

Persons: Morgan Stanley, Mark Purcell, Richard Vosser, Peter Verdult, Eli Lilly, Eli Lilly's, Lilly, Andrew Baum, Trung Huynh, That's, it's, Zepbound, Huynh, Citi's Baum, James Shin isn't, Michael Bloom, Christina Cheddar Berk, Angelica Peebles Organizations: Novo Nordisk, American Heart Association, cardiologists, JPMorgan, Citi, ., UBS, North American, Tandem Diabetes Care, Deutsche Bank

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

☆ There's a new entry into the weight loss drug boom. Here's the outlook for the stock
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

AstraZeneca is the latest player to enter the weight loss drug arena, a market which some analysts have forecasted could reach $100 billion by 2030 . The GLP-1 drug market is currently dominated by two players: Novo Nordisk , which sells Type 2 diabetes treatment Ozempic and weight loss medication Wegovy, and Eli Lilly , which sells Mounjaro as a treatment for Type 2 diabetes. Lilly just had the weight loss version of its drug, Zepbound , approved by the Food and Drug Administration. It's still early days for AstraZeneca's ECC5004 drug, which is being assessed in a U.S.-based phase 1 trial involving patients with Type 2 diabetes. He currently rates AstraZeneca stock as overweight.

Persons: Eccogene, Wegovy, Eli Lilly, Lilly, It's, Colin White, James Gordon, Morgan Stanley, Mark Purcell, AstraZeneca's Farxiga, Purcell, Michael Bloom, Christina Cheddar, Berk Organizations: AstraZeneca, Novo Nordisk, Food and Drug Administration, Centers for Disease Control, UBS, Wall Street, JPMorgan Locations: U.S

☆ The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it's a top pick
▼ + stars: | 2023-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

Sequence gives subscribers access to GLP-1 medications such as Novo Nordisk's Wegovy and Ozempic. Schenk said the concern about the drop in WW's average revenue per user "seems overblown" and has created a buying opportunity for the stock. Stabilizing core business WW has been focused on stabilizing its core weight loss business. Both developments are a positive for WW's Sequence business. Schenk estimates that around 6 million current or lapsed WW subscribers would qualify for treatment with obesity medication.

Persons: Sima Sistani, Morgan Stanley, Lauren Schenk, Eli Lilly, Schenk, Lilly, Novo Organizations: International, Nordisk's Wegovy, FDA, 3Q, and Drug Administration, Novo Nordisk Locations: Friday's, Novo

The sanctions imposed by Treasury Department's Office of Foreign Assets Control target third-party firms and people alleged to assist Moscow in procuring equipment needed on the battlefield, including suppliers and shippers. In addition, the State Department imposed diplomatic sanctions targeting Russian energy production and its metals and mining sector. Thursday's sanctions targets include Turkish national Berk Turken and his firms, which are alleged to have ties to Russian intelligence. The latest sanctions build on the thousands of financial penalties imposed on Russian infrastructure and its officials, banks and oligarchs. He accused the U.S. and its allies of ignoring Russia’s demand to prevent Ukraine from joining NATO and offer Moscow security guarantees.

Persons: Berk Turken, Janet Yellen, Russia “, ”, SWIFT, Vladimir Putin Organizations: WASHINGTON, United Arab, Treasury Department's, Foreign, State Department, Treasury Department, United Arab Emirates, Financial Engineering, VTB Bank, Central Bank, NATO Locations: United States, Turkey, China, United Arab Emirates, Ukraine, Turkish, Russian, Russia, UAE, ARX, U.S, Moscow

☆ Dinosaur-killing asteroid impact fouled Earth's atmosphere with dust
▼ + stars: | 2023-10-30 | by ( Will Dunham | ) www.reuters.com time to read: +5 min

The total amount of dust, they calculated, was about 2,000 gigatonnes - exceeding 11 times the weight of Mt. While prior research highlighted two other factors - sulfur released after the impact and soot from the wildfires - this study indicated dust played a larger role than previously known. "It was cold and dark for years," Vrije Universiteit Brussel planetary scientist and study co-author Philippe Claeys said. "While the sulfur stayed about eight to nine years, soot and silicate dust resided in the atmosphere for about 15 years after the impact. "Without the impact, my guess is that mammals - including us - had little chance to become the dominant organisms on this planet."

Persons: grâce, Cem Berk Senel, Philippe Claeys, Özgür Karatekin, Karatekin, Claeys, Will Dunham, Rosalba O'Brien Organizations: Royal Observatory of, Vrije Universiteit Brussel, Nature, Dinos, Thomson Locations: North Dakota, WASHINGTON, Yucatan, Everest, Dakota, Royal Observatory of Belgium, Vrije, Belgium

☆ Asteroid that doomed the dinosaurs halted key process for life on Earth, scientists say
▼ + stars: | 2023-10-30 | by ( Katie Hunt | ) edition.cnn.com time to read: +5 min

This dust blocked the sun to an extent that plants were unable to photosynthesize, a biological process critical for life, for almost two years afterward. Pim KaskesAn unexpected killing mechanismTo reach their findings, scientists developed a new computer model to simulate the global climate after the asteroid strike. Fossilized fish found at the site have revealed that the asteroid struck off Mexico’s Yucatán Peninsula in springtime. The team determined that this fine dust could have remained in the atmosphere for up to 15 years after the asteroid strike. The researchers suggested the global climate may have cooled by as much as 15 degrees Celsius.

Persons: ”, Cem Berk Senel, Pim Kaskes, ” Senel, Alfio Alessandro Chiarenza, Chiarenza Organizations: CNN, Royal Observatory of, …, University of Vigo Locations: Mexico, Royal Observatory of Belgium, “, North Dakota, Spain

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

Search resuls for: "Berk"

25 mentions found